ID | 1152 |
Name of the vaccine | Pentacel |
Microbe | Bacteria |
Disease name | Haemophilus influenzae type b (Hib) |
Name of bacteria | Haemophilus influenzae |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 6 weeks to 4 years |
Description of the vaccine | Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) vaccine
(DTaP vaccine). |
Name of the manufacturer | Sanofi Pasteur Limited and Sanofi Pasteur SA |
Name of the manufacturing country | Canada and France |
Year of manufacture | 2008 |
Clinical Phase status | Approved |
Bacterial strain | Anaerobic gram-negative coccobacillus. |
Efficacy | Study with H. influenzae type b polysaccharide vaccine in Finland. |
Vaccine formulation | Liquid vaccine |
Dosage | Four dose immunization series administered at 2, 4, 6 and 15-18 months. |
Mechanism of action | Anti-PRP level of 0.15 mcg/mL : Minimal protection
Greater than 1.0 mcg/mL : protection through one-year period |
Route of administration | Intramuscular |
Indications | The safety and effectiveness of Pentacel in infants less than 6 weeks of age and in children 5 to 16 years of age have not been established. |
Export | Distributed by- Sanofi Pasteur Inc. , USA |
Approval | US FDA |
Adjuvant | Aluminium phosphate |
Repurposing | For tetanus, pertussis, poliovirus and diphtheria. |
Side effects of vaccine | Fussiness, inconsolable crying, fever, tenderness and increase in arm circumference. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT00804284 |
Reference | https://www.fda.gov/media/74385/download |
Other name | NA |
Additional Links | NA
|